4D MOLECULAR THERAPEUTICS IN

FDMTNASDAQ

🏆 #2639 by market capEarnings Nov 11US Equity

$11.65▲ $0.18 (+1.57%)

Live

1h▲ 1.1%

24h▲ 1.6%

7d▲ 13.2%

14d▲ 21.5%

30d▲ 3.1%

1y▲ 89.3%

🏦Market Cap

$609M

Small Cap

📈Revenue Growth (YoY)

+230194.6%

High Growth

📊Gross Margin

-12.4%

Thin

💵FCF Margin

-147.4%

Thin

⚖️P/S Ratio

6.8x

Fair

Otter Score

Fair

Trading Snapshot

Day Range: $11.49 – $11.83
52-Week Range: $5.97 – $14.00
Volume: $2.35B
Avg Volume: $2.53B
Shares Outstanding: 52.3M
Next Earnings: Sep 27, 2026

Fundamentals Snapshot

Annual Revenue: $85M
Last Q Revenue: $3M
P/E Ratio: -4.3
P/S Ratio: 6.8x
EPS (TTM): $-2.36
Dividend Yield: 0.00%

Why Investors Own FDMT

✓High-growth profile — revenue up +13.3% YoY with expanding US Equity exposure.
✓Healthy economics — 72% gross margin and 12% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$85M▲ +16.0% YoY

Gross Margin (TTM)

72.1%▲ +4.1% YoY

Operating Income (TTM)

$27M▲ +16.0% YoY

Free Cash Flow (TTM)

$11M▲ +16.0% YoY

About 4D MOLECULAR THERAPEUTICS IN

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.

🦦